ClinicalTrials.govpublic full text
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age
covid-19, covid-19 vaccine, healthy population, booster, heterologous, children, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 802538
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.